Harvard Bioscience (HBIO) Tops Q4 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/26/2026
- Equities end higher as Anthropic's IPO filing buoys AI stocks
- Anthropic files for Nasdaq IPO as revenue jumps to $16.3 billion
- Meta reverses losses to rise as investors weigh $35 billion AI funding plan
- Post-election relief ahead for markets, says Morgan Stanley
- Musk says SpaceX raised $40 billion in debt, warns of neocloud collapse
Tweet
Share
E-mailGet Alerts HBIO Hot Sheet
Price: $8.32 +1.09%
Revenue Growth %: +6.1%
Financial Fact:
Net Income: -1.64M
Today's EPS Names:
JBLU, SICP, OMID, More
Revenue Growth %: +6.1%
Financial Fact:
Net Income: -1.64M
Today's EPS Names:
JBLU, SICP, OMID, More
Join SI Premium – FREE
Harvard Bioscience (NASDAQ: HBIO) reported Q4 EPS of $0.06, $0.01 better than the analyst estimate of $0.05. Revenue for the quarter came in at $24.6 million versus the consensus estimate of $24.15 million.
GUIDANCE:
Harvard Bioscience sees Q1 2025 revenue of $19-21 million.
For earnings history and earnings-related data on Harvard Bioscience (HBIO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- JetBlue Airways (JBLU) Misses Q3 EPS by 6c, Misses on Revenue
- Nucor (NUE) Reports In-Line Q3 EPS; offers outlook
- Chicopee Bancorp (CBNK) Misses Q3 EPS by 3c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
